Monitor for future disclosures on Yu Ding's capital strategy given the company's $4M market cap and likely funding needs; watch for potential Asia-focused partnerships or financings given new executives' regional expertise
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $1.75entry
- T+1 · 7mo ago −8.57%α −8.63% · $1.60
- T+5 · 7mo ago +17.71%α +13.58% · $2.06
- T+20 · 7mo ago +22.86%α +13.87% · $2.15
- T+60 · 5mo ago +68.00%α +54.53% · $2.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Indaptus Therapeutics announced the resignation of CFO Nir Sassi and the immediate appointment of Yu Ding as new CFO, along with the appointment of Qinglai Lu to the Board and Audit Committee. The leadership changes appear planned, with no disclosed disagreements, and bring fresh financial and Asia-Pacific market expertise to the company.
Key Facts
- CFO Nir Sassi resigned effective April 1, 2026, with no disclosed disagreement with the company
- Yu Ding appointed as new CFO effective immediately, bringing 20+ years of experience from CFO roles at Shanghai and Hong Kong-listed auto firms
- Qinglai Lu appointed to Board of Directors (effective April 8, 2026) and Audit Committee, with extensive finance and Web3 investment experience in Asia-Pacific
- Matthew McMurdo resigned from Audit Committee concurrent with Lu's appointment
- No compensation details or employment agreements filed with this 8-K
Financial Impact
No immediate financial impact disclosed; leadership transition may influence future capital raising and Asia strategy
Risk Factors
- Execution risk during CFO transition at a micro-cap biotech with limited resources
- Potential distraction from R&D priorities during leadership change
- No immediate insight into compensation costs for new executives
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-015079 |
| Document: 0001493152-26-015079-index-headers.html | 0001493152-26-015079 |
| Document: 0001493152-26-015079-index.html | 0001493152-26-015079 |
| Document: 0001493152-26-015079.txt | 0001493152-26-015079 |
Track record
20 reports on INDP
4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers